摘要
目的探究对急性脑梗死伴认知障碍的患者应用丁苯酞联合奥拉西坦的疗效并指导临床应用。方法选取本院2016年6月～2017年6月本院收治的64例急性脑梗死伴认知障碍的患者作为研究对象,并随机分为观察组(n=32)和对照组(n=32)。两组患者同时给予急性脑梗死的常规治疗,对照组患者给予奥拉西坦口服,而观察组则在对照组的基础上加服丁苯酞软胶囊。比较治疗前后两组患者的MoCA评分、MMSE评分、Barthel评分以及不良反应的发生情况。结果两组患者治疗前MoCA评分和MMSE评分,差异无统计学意义(P> 0.05),而治疗后,两组患者评分均显著提高,且观察组患者MoCA评分和MMSE评分均显著高于对照组,差异有统计学意义(P <0.05);治疗前,两组患者的Barthel评分差异无统计学意义(P> 0.05),治疗后,两组患者Barthel评分均提高,且观察组评分高于对照组,差异有统计学意义(P <0.05);观察组中出现1例头晕,对照组出现1例失眠,1例食欲减退,观察组不良反应发生率(3.13%)较对照组(6.25%)低,差异无统计学意义(P> 0.05)。结论丁苯酞联合奥拉西坦应用于急性脑梗死伴认知功能障碍的患者可以显著改善认知功能和日常生活能力,且无显著不良反应增加,临床应用前景光明。
Objective To explore the efficacy of butylphthalide combined with oxiracetam in patients with acute cerebral infarction and cognitive impairment and to guide clinical application. Methods Sixty-four patients with acute cerebral infarction with cognitive impairment in our hospital from June 2016 to June 2017 were randomly divided into the observation group (n=32) and the control group (n=32).Patients in the control group were given oxiracetam,while the observation group was treated with butylphthalide on the basis of the control group.The cognitive function,activities of daily living and the incidence of adverse reactions were compared between the two groups. Results There was no significant difference in MoCA score and MMSE score between the two groups before treatment (P > 0.05),after treatment,the scores of the two groups were significantly improved,and the MoCA score and MMSE score of the observation group were significantly higher than the control group,the difference was statistically significant (P < 0.05);Before treatment,there was no significant difference in Barthel score between the two groups (P > 0.05).After treatment,the Barthel scores of the two groups were increased,and the scores of the observation group were higher than the control group,the difference was statistically significant (P < 0.05);There was 1 case of dizziness in the observation group,1 case of insomnia in the control group,and 1 case of loss of appetite.The incidence of adverse reactions in the observation group (3.13%) was lower than that in the control group (6.25%),and the difference was no statistically significant (P > 0.05). Conclusion The combination of butylphthalide and oxiracetam in patients with acute cerebral infarction and cognitive dysfunction can significantly improve cognitive function and daily living ability,and there is no significant adverse reaction,and the clinical application prospect is bright.
作者
黎希年
洪荣庆
曾纪超
张勇
罗春雷
LI Xinian;HONG Rongqing;ZENG Jichao;ZHANG Yong;LUO Chunlei(Department of Neurology,Yangjiang Traditional Chinese Medicine Hospital,Yangjiang 529500,China)
出处
《中国医药科学》
2019年第3期66-68,共3页
China Medicine And Pharmacy
关键词
脑梗死
丁苯酞
奥拉西坦
认知功能障碍
Cerebral infarction
Butylphthalide
Oxiracetam
Cognitive dysfunction
